As a result of current developments in systemic therapy, RCC patients can now receive a number of regimens, including bevacizumab, which inhibits VEGF signaling, as well as mTOR inhibitors and immune checkpoint inhibitors (ICIs) [16]. This evidence concerns the gene MTOR and renal cell carcinoma.